Innate Pharma sets Sept. 17 H1 2026 update call
Rhea-AI Filing Summary
Innate Pharma S.A. (IPHA) announced it will host a conference call and webcast on September 17, 2026 to provide a business update for the first half of 2026. The event will feature the company’s senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, and Chief Financial Officer.
Innate Pharma is a clinical-stage biotechnology company focused on immunotherapies for cancer, with a proprietary pipeline centered on antibody-drug conjugates such as IPH4502 targeting Nectin-4, and partnered late-stage assets lacutamab with Sobi and monalizumab with AstraZeneca. The webcast replay will be available for 90 days on the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Event date: September 17, 2026
Event time CEST: 2:00 p.m. CEST
Event time EDT: 8:00 a.m. EDT
+1 more
4 metrics
Event date
September 17, 2026
Date of Innate Pharma’s first-half 2026 business update call
Event time CEST
2:00 p.m. CEST
Scheduled start time of the conference call in Europe
Event time EDT
8:00 a.m. EDT
Scheduled start time of the conference call in North America
Webcast replay period
90 days
Duration that the webcast replay will be available on the company website
Key Terms
immunotherapies, antibody-drug conjugates, Nectin-4, non-small cell lung cancer, +2 more
6 terms
immunotherapies medical
"developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
antibody-drug conjugates medical
"proprietary pipeline is centered on antibody-drug conjugates (ADCs)"
A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.
Nectin-4 medical
"IPH4502, a differentiated Nectin-4 ADC in clinical development"
A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.
non-small cell lung cancer medical
"monalizumab, developed with AstraZeneca for non-small cell lung cancer"
A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.
Universal Registration Document regulatory
"section of the Universal Registration Document filed with the French"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
forward-looking information regulatory
"Disclaimer on forward-looking information and risk factors"
Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.
FAQ
What is Innate Pharma (IPHA) announcing in this Form 6-K?
Innate Pharma is announcing a conference call and webcast on September 17, 2026, during which management will provide a business update for the first half of 2026. The event will include senior executives across clinical, operational and financial functions.
When will the Innate Pharma (IPHA) call for first half 2026 take place?
The call will take place on September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. Investors can access the event via webcast or conference call links provided in the company’s investor relations section.
Who from Innate Pharma (IPHA) will participate in the September 17, 2026 call?
Participants will include Jonathan Dickinson (CEO), Markus Jensen (VP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer) and Frédéric Lombard (SVP, Chief Financial Officer).
What is Innate Pharma’s core business focus?
Innate Pharma is a clinical-stage biotechnology company developing cancer immunotherapies. It focuses on next-generation antibody therapeutics, particularly antibody-drug conjugates (ADCs), and advances partnered immuno-oncology assets in cutaneous T-cell lymphomas and non-small cell lung cancer.
Which key drug candidates are highlighted for Innate Pharma (IPHA)?
Innate highlights IPH4502, a differentiated Nectin-4 antibody-drug conjugate in clinical development for solid tumors, along with partnered late-stage assets lacutamab with Sobi for cutaneous T-cell lymphomas and monalizumab with AstraZeneca for non-small cell lung cancer.
How long will the replay of the Innate Pharma September 17, 2026 webcast be available?
A replay of the webcast will be available on Innate Pharma’s website for 90 days following the event, allowing investors and stakeholders to review the first-half 2026 business update.
AI-generated analysis. How Rhea-AI works. Not financial advice.
